^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    netazepide (YF476)

    i
    Other names: YF476, YF-476, YF 476
    Associations

    News

    Trials
    Company:
    Trio Medicines
    Drug class:
    CCK2-R antagonist
    Associations

    News

    Trials
    6years
    Netazepide Inhibits Expression of Pappalysin 2 in Type-1 Gastric Neuroendocrine Tumors. (PubMed, Cell Mol Gastroenterol Hepatol)
    In an analysis of human gNETS and mice, we found that gastrin upregulates expression of gastric PAPPA2. Increased PAPPA2 alters IGF bioavailability, cell migration, and tissue remodeling, which are involved in type-1 gNET development. These effects are inhibited by netazepide.
    Journal
    |
    IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    netazepide (YF476)